Trevi Therapeutics, Inc.
TRVI
$6.47
$0.121.89%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -11.42M | -13.24M | -12.35M | -10.90M | -7.82M |
| Total Depreciation and Amortization | 38.00K | 36.00K | 38.00K | 35.00K | 35.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | 390.00K |
| Total Other Non-Cash Items | 818.00K | 497.00K | 904.00K | 462.00K | 301.00K |
| Change in Net Operating Assets | 1.01M | 3.15M | 2.73M | -62.00K | 736.00K |
| Cash from Operations | -9.55M | -9.56M | -8.68M | -10.47M | -6.36M |
| Capital Expenditure | -7.00K | 0.00 | -28.00K | -- | -22.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -23.87M | 7.67M | 2.80M | -8.09M | 12.87M |
| Cash from Investing | -23.87M | 7.67M | 2.77M | -8.09M | 12.85M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -31.00K | -32.00K | -31.00K | -32.00K | -32.00K |
| Issuance of Common Stock | 51.50M | 5.01M | 5.10M | 4.00K | 36.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -58.00K |
| Cash from Financing | 51.47M | 4.98M | 5.07M | -28.00K | -54.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 18.05M | 3.09M | -848.00K | -18.59M | 6.43M |